Association of CYP2C19 genotype with type 2 diabetes

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Health

ISSN Print: 1949-4998
ISSN Online: 1949-5005
www.scirp.org/journal/health
E-mail: health@scirp.org

Google-based Impact Factor: 0.74
Citations h5-index & Ranking*

Journals Menu

"Association of CYP2C19 genotype with type 2 diabetes"
written by Carlos Hoyo-Vadillo, Jaime Garcia-Mena, Adán Valladares, Caterina R. Venturelli, Niels Wacher-Rodarte, Jesús Kumate, Miguel Cruz,
published by Health, Vol.2 No.10, 2010

has been cited by the following article(s):

Google Scholar
CrossRef

[1]	Polyunsaturated fatty acids, specialized pro-resolving mediators, and targeting inflammation resolution in the age of precision nutrition
	2021

[2]	Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner
	2020

[3]	Risk factors for cardiovascular disease in Mexican adults
	2018

[4]	Cytochrome P450: Polymorphisms and roles in Cancer, Diabetes and Atherosclerosis
	Asian Pacific journal of cancer prevention: APJCP, 2018

[5]	CYTOCHROME P450 CYP1B1* 2 GENE AND ITS ASSOCIATION WITH T2D IN TABUK POPULATION, NORTHWESTERN REGION OF SAUDI ARABIA
	2018

[6]	Factores de riesgo para enfermedad cardiovascular en adultos mexicanos/Risk factors for cardiovascular disease in Mexican adults
	Revista Medica MD, 2017

[7]	Actividad de CYP2C19 y factores de riesgo cardiovascular en pacientes con síndrome coronario agudo
	Medicina Clínica, 2017

[8]	Revista Médica
	2017

[9]	CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome
	Medicina Clínica (English Edition), 2017

[10]	Oporność na leki przeciwpłytkowe: przyczyny i możliwości diagnostyki
	Problemy Nauk Stosowanych, 2016

[11]	CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
	The Pharmacogenomics Journal, 2015

[12]	Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19* 17 to develop the ultrarapid metabolizer …
	Journal of Genetics, 2015

[13]	Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19* 17 to develop the ultrarapid metabolizer phenotype
	Journal of genetics, 2015

[14]	Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid …
	Journal of Genetics, 2015

[15]	糖尿病状态下CYP450s 酶活性改变及其在糖尿病病情发展中的作用
	中国药科大学学报, 2014

[16]	Oporność na leki przeciwpłytkowe u pacjentów z chorobami układu krążenia i cukrzycą Resistance to antiplatelet drugs in patients with cardiovascular diseases and diabetes
	W Piechota - pnmedycznych.pl, 2014

[17]	Genetic variability of CYP2C19 in a Mexican population: Contribution to the knowledge of the inheritance pattern of CYP2C19* 17 to develop the ultra-rapid metabolizer phenotype
	JSF HERNANDEZ-ZARAGOZA, J FRANCISCO… - ias.ac.in, 2014

[18]	糖尿病状态下 CYP450s 酶活性改变及其在糖尿病病情发展中的作用
	2014

[19]	Resistance to antiplatelet drugs in patients with cardiovascular diseases and diabetes
	Postępy Nauk Medycznych, 2013

[20]	Demographic Differences by Age, BMI, Gender and Disease States of Phase I and Phase II Enzyme Activities in Cryopreserved Human Hepatocytes
	T Moeller, S Dennell, T Rose, C Watt - ww.bioreclamation.com, 2013

[21]	Cytochrome P450 genetic polymorphisms of Mexican indigenous populations
	Drug metabolism and drug interactions, 2013

[22]	Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico
	Genetic testing and …, 2012

[23]	Impact of clopidogrel treatment on platelet function and thrombogenecity in diabetic patients undergoing elective coronary stenting
	Journal of Diabetes Mellitus, 2012

[24]	Distribution of
	2012

[1]	Pharmacogenetics of CYP2C1917: Functional and Clinical Implications of CYP2C1917 - rs12248560 (c.-806C>T) in the Development of Type 2 Diabetes Biomedical and Pharmacology Journal, 2022 DOI:10.13005/bpj/2528

[2]	Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C93 and CYP2C193 Gene Variations With Type 2 Diabetes: A Case-Control Study Current Drug Metabolism, 2020 DOI:10.2174/1389200221999201027200931

[3]	Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner The FASEB Journal, 2020 DOI:10.1096/fj.202000830R

[4]	Actividad de CYP2C19 y factores de riesgo cardiovascular en pacientes con síndrome coronario agudo Medicina Clínica, 2017 DOI:10.1016/j.medcli.2017.02.035

[5]	CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome Medicina Clínica (English Edition), 2017 DOI:10.1016/j.medcle.2017.02.030

[6]	CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy The Pharmacogenomics Journal, 2016 DOI:10.1038/tpj.2015.45

[7]	Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C1917 to develop the ultrarapid metabolizer phenotype Journal of Genetics*, 2015 DOI:10.1007/s12041-015-0477-1

[8]	Impact of clopidogrel treatment on platelet function and thrombogenecity in diabetic patients undergoing elective coronary stenting Journal of Diabetes Mellitus, 2012 DOI:10.4236/jdm.2012.22025

[9]	Distribution ofCYP2D6andCYP2C19Polymorphisms Associated with Poor Metabolizer Phenotype in Five Amerindian Groups and Western Mestizos from Mexico Genetic Testing and Molecular Biomarkers, 2012 DOI:10.1089/gtmb.2012.0055

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Health

Health

Journals Menu

Home

About SCIRP

Service

Policies